Relay Therapeutics, Inc. (NASDAQ: RLAY ) is working at the cutting edge of precision oncology. RLY-2608, its lead asset, is an allosteric and pan-mutant PI3Kα inhibitor targeting breast cancer. This molecule is currently in phase 3 trials after producingDubai-based investor focused on building a resilient, income-generating portfolio with a long-term growth mindset. My approach is primarily long-only, blending dividend-paying equities, REITs, and other income strategies with selective growth opportunities. ...

Relay Therapeutics (NASDAQ: RLAY ) is working at the cutting edge of precision oncology. RLY-2608, its lead asset, is an allosteric and pan-mutant PI3Kα inhibitor targeting breast cancer. This molecule is currently in phase 3 trials, after producing positive interimDubai-based investor focused on building a resilient, income-generating portfolio with a long-term growth mindset. My approach is primarily long-only, blending dividend-paying equities, REITs, and other income strategies with selective growth opp ...

Core Insights - Whitehawk Therapeutics presented data on Protein Tyrosine Kinase 7 (PTK7) as a promising target for antibody-drug conjugates (ADCs) at the 2025 AACR-NCI-EORTC International Conference, highlighting its expression in approximately 70% of solid tumors [1][6][3] Group 1: PTK7 Characteristics - PTK7 is the third most highly expressed tumor marker among ADC targets, following HER2 and HER3, with stable expression across various cancer types and stages [6][1] - The analysis involved over 157,000 tumor samples, confirming PTK7's broad expression in solid tumors, particularly in endometrial (7.4), ovarian (7.2), head and neck (7.1), non-small cell lung cancer (NSCLC) (6.9), and breast (6.7) tumors [6][3] Group 2: Development of HWK-007 - Whitehawk is advancing HWK-007, a PTK7-targeting ADC that utilizes a stable yet cleavable linker to deliver a Topoisomerase I (TOPO1) inhibitor payload, with plans to submit an Investigational New Drug application to the FDA by year-end [5][6] - The company aims to initiate clinical evaluations of HWK-007 in NSCLC, ovarian, and endometrial cancers, targeting nearly 750,000 patients in the US with PTK7-expressing cancers [7][5] Group 3: Collaboration and Future Outlook - The analysis was conducted in collaboration with Tempus AI, utilizing real-world data to characterize PTK7 expression for the first time [1][7] - The findings underscore the potential of PTK7 as a clinically meaningful target for ADCs, reinforcing Whitehawk's strategic focus on developing next-generation ADCs for a wide range of patients [5][6]

Market Performance - U.S. stocks experienced a positive trading session, with the Dow Jones index increasing by more than 500 points, closing up 1.19% at 47,289.61. The NASDAQ rose 1.27% to 23,232.48, and the S&P 500 gained 0.98% to 6,804.28 [1] - Communication services sector saw a rise of 1.2%, while energy stocks declined by 0.4% [1] Economic Indicators - The University of Michigan consumer sentiment index was revised down to 53.6 in October from a preliminary reading of 55 and compared to 55.1 in September [2][11] - The S&P Global services PMI increased to 55.2 in October from 54.2 in the previous month, exceeding market expectations of 53.5 [11] - The S&P Global manufacturing PMI rose to 52.2 in October from 52.0, also surpassing estimates of 52.0 [11] - The S&P Global composite PMI jumped to 54.8 in October from 53.9 in September [11] - Year-ahead inflation expectations in the U.S. decreased to 4.6% in October from 4.7% in September [11] Commodity Prices - Oil prices increased by 0.7% to $62.19, while gold prices decreased by 0.1% to $4,143.10. Silver fell by 0.4% to $48.530, and copper dropped by 0.2% to $5.0985 [5] International Markets - European shares were mostly higher, with the eurozone's STOXX 600 rising by 0.07%. Spain's IBEX 35 gained 0.15%, London's FTSE 100 rose by 0.32%, Germany's DAX 40 increased by 0.14%, while France's CAC 40 fell by 0.30% [6] - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.35%, Hong Kong's Hang Seng index up by 0.74%, and China's Shanghai Composite rising by 0.71%. India's BSE Sensex, however, fell by 0.41% [7] Company News - Wellgistics Health, Inc. shares surged by 229% to $1.3501 after signing a non-binding letter of intent with Datavault AI Inc. to integrate blockchain technology [9] - Genenta Science S.p.A. shares increased by 108% to $6.81 following an expanded collaboration with ANEMOCYTE [9] - Inhibrx Biosciences, Inc. shares rose by 74% to $49.26 after positive trial results for Ozekibart in chondrosarcoma [9] - Deckers Outdoor Corporation shares fell by 13% to $89.00 after reporting second-quarter results that missed revenue estimates [9] - MultiSensor AI Holdings, Inc. shares dropped by 46% to $0.7340 due to a $14 million private placement announcement [9] - MaxLinear, Inc. shares decreased by 13% to $15.31 following third-quarter results [9]

Accessibility StatementSkip Navigation BETHESDA, Md., Oct. 24, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. ("Advent") has closed. As a result of this acquisition, Advent is now a wholly owned subsidiary of NWBio. The Company anticipates that this acquisition will help enable efficiencies and scale-up of op ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. (Ålesund, 24 October 2025) Reference is made to the stock exchange notices published by Hofseth BioCare ASA ("HBC" or the "Company") earlier today regarding the launch of a private placement ...

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 months46% ORR observed among 48 evaluable patients in ovarian cancer cohort with a me ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If you currently own BioXcel stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about. ...

Key Takeaways Regeneron to post Q3 results on Oct. 28, with earnings forecast at $9.54 per share on $3.60B revenues.Dupixent profits likely rose on 26.2% higher sales across multiple approved disease indications.Strong demand for Eylea HD could offset declines in Eylea. Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. (REGN) reports third-quarter 2025 results on Oct. 28, 2025.The Zacks Consensus Estimate for revenues is pegged ...

Shares of Ocular Therapeutix (OCUL) have been struggling lately and have lost 6.2% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ...